Navigation Links
Covaris Installed Instrument Base Reaches 500 Units
Date:11/26/2008

WOBURN, Mass., Nov. 26 /PRNewswire/ -- Covaris Incorporated today announced that during the summer of 2008, the company celebrated the shipment of its 500th instrument unit and continued another successful year throughout 2008. To accommodate this rapid business growth, Covaris is both strengthening its sales and marketing organization as well as implementing a 50% expansion of its main facility.

The Covaris business was built upon the proprietary and patented AFA(TM) (Adaptive Focused Acoustics) technology. The AFA technology has the ability of impart both thermal and non-contact control of application processes, which, in many cases, could not be obtained prior to the development of AFA technology. This unique and sustainable competitive advantage enables Covaris to develop a broad range of applications in Genomics, Proteomics and Drug Discovery research.

"There has been an increased systematic acceptance of our technology over the past few years. We are pleased to see our sample preparation tools gaining market acceptance and incorporated into daily research investigations throughout research institutions and pharmaceutical companies, such as the Broad Institute, GlaxoSmithKline and Merck," said Jim Laugharn, President and CEO of Covaris, "with the help of our customers, we have developed and optimized solutions for various key applications, such as DNA shearing for next-gen sequencing, RNA extraction for gene expression profiling, analyte and small molecule extraction from difficult tissue samples, compound formulation, and ADME/Tox."

"I'm truly impressed with the solid technology and product platform Covaris has developed and its experienced team of people with well-balanced knowledge ranging from acoustic physics, mechanical engineering to biophysics and molecular biology," commented Jennifer Wu, the newly hired Director of Marketing, "I'm honored and excited to join Covaris to further expedite marketing programs, market development and customer experience enhancement."

About Covaris, Inc.

Covaris, Inc. is a rapidly growing life science instrument company. Its proprietary instrument platform, based on patented Adaptive Focused Acoustic (AFA) technology brings unsurpassed speed and efficiency to biological and chemical sample preparation. The AFA process, based on shock wave physics, delivers controlled, precise, and accurate energy to biological and chemical samples. The process is non-contact, isothermal, and rapid. Leading pharmaceutical and biotechnology companies worldwide are using Covaris instruments for RNA extraction, Compound Dissolution, Drug Metabolism tissue extraction, and much more. Information about Covaris is available at http://www.covarisinc.com.


'/>"/>
SOURCE Covaris Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. VisualSonics and Seno Medical Instruments Sign Exclusive Opto-Accoustic Licensing Agreement for Preclinical Research
2. Nikon Instruments Provides Donation to Help Clemson University Start New Core Microscopy Facility
3. Microplate Instrumentation & Supplies Market to Exceed $5.0 Billion by 2015, According to New Report by Global Industry Analysts, Inc
4. Nanoscience Instruments, Inc. Introduces All-Diamond AFM Probes
5. Nikon Instruments Appoints LABSCO its Clinical Distributor in Six States
6. Instrumentation Laboratory Announces Passion & Results Awards Program
7. MKS Instruments Announces Third Quarter 2008 Earnings Conference Call
8. Advanced Instruments Acquires D & F Control Systems Inc.
9. World Leader in Bench Top Flow Chemistry Instruments ThalesNano, Inc. Introduces an Industry First Seminar Series
10. Nanoscience Instruments, Inc. Announces Distribution of Nascatec's Complete Line of Unique AFM Probes and Sensors
11. World Leader in Bench-Top Flow Chemistry Instruments ThalesNano, Inc. Closes Funding Round
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 24, 2017  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), ... a Key Opinion Leader event to highlight new clinical ... poster presentation at the upcoming 2017 ASCO-SITC Immuno-Oncology Symposium ... will be held in-person and via live webcast on ... AM PST at the Lotte New York Palace Hotel ...
(Date:2/23/2017)... , Feb. 23, 2017 /PRNewswire/ - The Fight Against ... Cancer Research (OICR) are pleased to report that Fusion ... financing, with Johnson & Johnson Innovation – JJDC, Inc. ... venture groups HealthCap, TPG Biotechnology Partners, and Genesys Capital, ... ...
(Date:2/23/2017)... , Feb. 23, 2017  Imanis Life Sciences ... line of oncolytic vaccinia viruses for virotherapy research. ... part of Genelux,s proprietary, vaccinia virus-based technology platform ... to enter into a partnership with Genelux to ... vaccinia viruses for use in research," said Dr. ...
(Date:2/23/2017)... ... ... Today, researchers can fast-track sample collection and analysis for ... or SNPs of interest) using one, easy-to-collect saliva sample. With the addition of ... and other relevant biomarkers can be extensively studied through a non-invasive sample type. ...
Breaking Biology Technology:
(Date:2/7/2017)... Feb. 7, 2017 Zimmer Biomet Holdings, Inc. ... healthcare, will present at the LEERINK Partners 6th Annual ... Hotel on Wednesday, February 15, 2017 at 10 a.m. ... the presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  ... conference via Zimmer Biomet,s Investor Relations website at ...
(Date:2/2/2017)... , Feb. 2, 2017   TapImmune, ... clinical-stage immuno-oncology company specializing in the development of ... the treatment of cancer and metastatic disease, announced ... and GMP manufacturing of a second clinical lot ... targeting folate receptor alpha. The manufactured vaccine product ...
(Date:1/30/2017)...   Invitae Corporation (NYSE: NVTA ... today announced that it will report its fourth quarter ... on Monday, February 13, 2017, and Invitae,s management team ... p.m. Eastern / 1:45 p.m. Pacific. ... financial results, guidance, and recent developments and will spend ...
Breaking Biology News(10 mins):